Tissue engineering for in vitro analysis of matrix metalloproteinases in the pathogenesis of keloid lesions

JAMA Facial Plastic Surgery

Volumn 15, Issue 6, 2013, Pages 448-456

  Li, Hanwei ^a   Nahas, Zayna ^a   Feng, Felicia ^a   Elisseeff, Jennifer H ^a   Boahene, Kofi ^b  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BIOMATERIAL; COLLAGEN; COLLAGEN TYPE 1; COLLAGENASE 3; GELATINASE B; LAMININ; MACROGOL DERIVATIVE; MATRIGEL; MATRIX METALLOPROTEINASE; MMP13 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; POLY(ETHYLENE GLYCOL)DIACRYLATE; PROTEOGLYCAN;

ARTICLE; DRUG COMBINATION; ENZYMOLOGY; FIBROBLAST; HUMAN; IN VITRO STUDY; KELOID; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE ENGINEERING; UPREGULATION; WOUND HEALING;

BIOCOMPATIBLE MATERIALS; BIOLOGICAL MARKERS; COLLAGEN; COLLAGEN TYPE I; DRUG COMBINATIONS; FIBROBLASTS; HUMANS; KELOID; LAMININ; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; POLYETHYLENE GLYCOLS; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ENGINEERING; UP-REGULATION; WOUND HEALING;

EID: 84892703087     PISSN: 21686076     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamafacial.2013.1211     Document Type: Article

References (25)

1. Clark RA, Ghosh K, Tonnesen MG. Tissue engineering for cutaneous wounds. J Invest Dermatol. 2007;127(5):1018-1029.
2. Pollack SV.Wound healing: a review, I: the biology of wound healing. J Dermatol Surg Oncol. 1979;5(5):389-393.
3. Tredget EE, Nedelec B, Scott PG, Ghahary A. Hypertrophic scars, keloids, and contractures: the cellular and molecular basis for therapy. Surg Clin North Am. 1997;77(3):701-730.
4. Al-Attar A,Mess S, Thomassen JM, Kauffman CL, Davison SP. Keloid pathogenesis and treatment. Plast Reconstr Surg. 2006;117(1):286-300.
5. Younai S, Nichter LS,Wellisz T, Reinisch J, Nimni ME, Tuan TL. Modulation of collagen synthesis by transforming growth factor-beta in keloid and hypertrophic scar fibroblasts. Ann Plast Surg. 1994;33(2):148-151.
6. Bettinger DA, Yager DR, Diegelmann RF, Cohen IK. The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis. Plast Reconstr Surg. 1996;98(5):827-833.
7. Kischer CW,Wagner HN Jr, Pindur J, et al. Increased fibronectin production by cell lines from hypertrophic scar and keloid. Connect Tissue Res. 1989;23(4):279-288.
8. Alaish SM, Yager DR, Diegelmann RF, Cohen IK. Hyaluronic acidmetabolism in keloid fibroblasts. J Pediatr Surg. 1995;30(7):949-952.
9. Hunzelmann N, Anders S, Sollberg S, Schonherr E, Krieg T. Co-ordinate induction of collagen type I and biglycan expression in keloids. Br J Dermatol. 1996;135(3):394-399.
10. Chen MA, Davidson TM. Scar management: prevention and treatment strategies. Curr Opin Otolaryngol Head Neck Surg. 2005;13(4):242-247.
11. FujiwaraM, Muragaki Y, Ooshima A. Keloid-derived fibroblasts show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase formigration. Br J Dermatol. 2005;153(2):295-300.
12. Seifert O, Bayat A, Geffers R, et al. Identification of unique gene expression patterns within different lesional sites of keloids.Wound Repair Regen. 2008;16(2):254-265.
13. Uchida G, Yoshimura K, Kitano Y, Okazaki M, Harii K. Tretinoin reverses upregulation of matrix metalloproteinase-13 in human keloid-derived fibroblasts. Exp Dermatol. 2003;12(suppl 2):35-42.
14. Konttinen YT, AinolaM, Valleala H, et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis. 1999;58(11):691-697.
15. Ma L, Teruya-Feldstein J,Weinberg RA. Tumour invasion and metastasis initiated bymicroRNA-10b in breast cancer. Nature. 2007;449(7163): 682-688.
16. Repesh LA. A new in vitro assay for quantitating tumor cell invasion. Invasion Metastasis. 1989;9(3):192-208.
17. Lal A, Glazer CA, Martinson HM, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 2002;62(12):3335-3339.
18. Igarashi A, Nashiro K, Kikuchi K, et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol. 1996;106(4):729-733.
19. Leask A, Holmes A, Abraham DJ. Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis. Curr Rheumatol Rep. 2002;4(2):136-142.
20. Yeo TK, Brown L, Dvorak HF. Alterations in proteoglycan synthesis common to healing wounds and tumors. Am J Pathol. 1991;138(6):1437-1450.
21. Reed CC, Iozzo RV. The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J. 2002;19(4-5):249-255.
22. Lu F, Gao J, Ogawa R, Hyakusoku H, Ou C. Biological differences between fibroblasts derived from peripheral and central areas of keloid tissues. Plast Reconstr Surg. 2007;120(3):625-630.
23. Sayah DN, Soo C, ShawWW, et al. Downregulation of apoptosis-related genes in keloid tissues. J Surg Res. 1999;87(2):209-216.
24. Werner S, Krieg T, Smola H. Keratinocytefibroblast interactions in wound healing. J Invest Dermatol. 2007;127(5):998-1008.
25. Lim IJ, Phan TT, Bay BH, et al. Fibroblasts cocultured with keloid keratinocytes: normal fibroblasts secrete collagen in a keloidlike manner. Am J Physiol Cell Physiol. 2002;283(1):C212-C222.